Martin Schuster
Psychiatry · Sherman Oaks, CANPI 1114973203
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,578 of the $7,043 with a category attached, or 79.2%. It is spread thinly across 19 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 274 payments — averaging $25.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- E.r. Squibb & Sons, L.L.C.$762
- Boehringer Ingelheim$718
- Sunovion Pharmaceuticals Inc.$605
- Vanda Pharmaceuticals Inc.$543
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$475
- plus $2K from 13 others
Across 800 payments — averaging $7960.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$2M
- Sunovion Pharmaceuticals Inc.$1.6M
- Teva Pharmaceuticals USA, Inc.$1.4M
- Hoffmann-la Roche Limited$496K
- Merck$442K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$182K
- plus $243K from 7 others
What the payments were for
- Consulting fees$72010%
- Travel & lodging$69110%
- Food & beverage$5,57879%
- Education$551%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 86 | $1,621 |
| E.r. Squibb & Sons, L.L.C. | 3 | $762 |
| Boehringer Ingelheim | 3 | $718 |
| Sunovion Pharmaceuticals Inc. | 34 | $605 |
| Vanda Pharmaceuticals Inc. | 25 | $543 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $475 |
| Teva Pharmaceuticals USA, Inc. | 25 | $410 |
| Bausch Health US, LLC | 18 | $363 |
| Amgen | 13 | $309 |
| Otsuka America Pharmaceutical, Inc. | 13 | $284 |
| Alkermes, Inc. | 10 | $257 |
| Johnson & Johnson | 11 | $238 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $92 |
| Merck | 4 | $89 |
| Almatica Pharma LLC | 3 | $79 |
| Neurocrine Biosciences, Inc. | 3 | $76 |
| Axsome Therapeutics, Inc. | 3 | $76 |
| GE HealthCare | 1 | $31 |
| Lundbeck LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,043 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 11 | $15,737 |
| VraylarCariprazine Hcl | 11 | $14,504 |
| XanaxAlprazolam | 12 | $11,009 |
| Clomipramine Hcl | 11 | $6,672 |
| Lurasidone Hcl | 21 | $5,654 |
| Bupropion XlBupropion Hcl | 195 | $5,385 |
| Aripiprazole | 52 | $5,148 |
| VyvanseLisdexamfetamine Dimesylate | 13 | $5,123 |
| CelexaCitalopram Hydrobromide | 11 | $4,907 |
| Divalproex Sodium ErDivalproex Sodium | 31 | $3,846 |
| Duloxetine Hcl | 67 | $2,331 |
| Trazodone Hcl | 108 | $1,491 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 29 | $1,448 |
| Memantine Hcl | 15 | $1,234 |
| Quetiapine Fumarate | 72 | $1,154 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $284 | $15,73711 claims |
| AbbVieVraylar | $1,621 | $14,50411 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $92 | $5,12313 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $410 | $69411 claims |
| Almatica Pharma LLCSertraline Hcl | $79 | $42361 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Sherman Oaks
- Thomas ShiovitzSherman Oaks$151K
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.